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Abstract
© Bionika Media Ltd. Objective. To evaluate the efficacy and safety of an agent containing
ethinylestradiol (EE) in combination with chlormadinone acetate (CMA) in contraceptive-needing
patients within the framework of the pharmacological epidemiological observational project.
Subjects  and methods.  The study enrolled  161 female  patients  needing contraception.  All
patients had no contraindications to combined oral contraceptives (COCs) and conditions in
which COCs should be used with caution. All the women took EE in combination with CMA in a
21/7 cyclic regimen for contraception. To evaluate its efficacy and safety, the occurrence of
pregnancy was assessed within 6 months of EE/CMA intake. To estimate safety parameters, the
changes in body weight, blood pressure, and hemostatic parameters that characterized the risk
of  hypercoagulation  disorders  were  assessed.  Results.  During  the  follow-up,  no  pregnancy
occurred  in  the  patients  included  in  the  study.  Significant  changes  in  weight  gain,  blood
pressure, and improvement in the blood coagulation potential were not observed. The hormonal
contraceptive with CMA demonstrated an additional positive effect on the women’s emotional
state. Conclusion. The findings may conclude that EE in combination with CMA is highly effective
and safe and may also highlight its additional positive effects.
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